Cyclerion Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	4.57	3.23	7.57	13.38	53.96	54.4
Cash & Short-Term Investments	4.57	3.23	7.57	13.38	53.96	54.4
Cash Growth	59.05%	-57.31%	-43.42%	-75.20%	-0.80%	-42.68%
Accounts Receivable	0.1	0.56	-	0.1	0.1	0.13
Other Current Assets	0.4	0.44	0.45	1.34	1.4	3.98
Total Current Assets	5.07	4.23	8.02	14.82	55.46	58.5
Net Property, Plant & Equipment	-	-	-	1.22	1.47	50.27
Long-Term Investments	5.35	5.35	5.35	-	-	-
Other Long-Term Assets	-	-	-	2.04	2.41	6.61
Total Assets	10.42	9.58	13.37	18.08	59.33	115.38
Accounts Payable	0.48	0.39	1.2	2.97	1.83	1.44
Accrued Expenses	0.4	0.34	0.89	4.66	9.26	8.72
Short-Term Debt	-	-	-	-	-	3.51
Current Portion of Leases	-	-	-	-	-	3.29
Total Current Liabilities	0.88	0.73	2.09	7.63	11.09	16.95
Long-Term Leases	-	-	-	-	-	38.93
Total Long-Term Liabilities	-	-	-	-	-	38.93
Total Liabilities	0.88	0.73	2.09	7.63	11.09	55.89
Additional Paid-in Capital	279.76	276.34	275.72	269.63	263.35	222.95
Accumulated Other Comprehensive Income	-	-	-0.01	-0.02	-0.02	-0.03
Retained Earnings	-270.22	-267.49	-264.42	-259.15	-215.08	-163.43
Shareholders' Equity	9.54	8.85	11.29	10.45	48.25	59.49
Total Liabilities & Equity	10.42	9.58	13.37	18.08	59.33	115.38
Total Debt	-	0	0	0	0	45.74
Net Cash (Debt)	4.57	3.23	7.57	13.38	53.96	8.66
Net Cash Growth	41.34%	-57.31%	-43.42%	-75.20%	523.11%	-58.71%
Net Cash Per Share	1.16	1.28	3.24	6.16	27.57	5.70
Book Value	9.54	8.85	11.29	10.45	48.25	59.49
Book Value Per Share	2.43	3.51	4.83	4.81	24.65	39.14
Tangible Book Value	9.54	8.85	11.29	10.45	48.25	59.49
Tangible Book Value Per Share	2.43	3.51	4.83	4.81	24.65	39.14

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q